Royalty Pharma (STU:RPD) Scaled Net Operating Assets : 0.89 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Royalty Pharma's operating assets for the quarter that ended in Mar. 2024 was €13,431 Mil. Royalty Pharma's operating liabilities for the quarter that ended in Mar. 2024 was €118 Mil. Royalty Pharma's Total Assets for the quarter that ended in Dec. 2023 was €15,022 Mil. Therefore, Royalty Pharma's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.89.

Royalty Pharma Scaled Net Operating Assets Historical Data

The historical data trend for Royalty Pharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Scaled Net Operating Assets Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

1.04

0.96

0.98

0.87

Royalty Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.85	0.81	0.83	0.93	0.89

Competitive Comparison of Royalty Pharma's Scaled Net Operating Assets

For the Biotechnology subindustry, Royalty Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Royalty Pharma's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Royalty Pharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's Scaled Net Operating Assets falls into.

Royalty Pharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Royalty Pharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(13890.81	-	148.808)	/	15871.912
=	0.87

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	15022.157	-	1131.347
=	13890.81

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	5774.864	-	5626.056	-	0
=	148.808

Royalty Pharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(13430.532	-	117.57)	/	15022.157
=	0.89

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	14840.415	-	1409.883
=	13430.532

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	5765.796	-	5648.226	-	0
=	117.57

Royalty Pharma Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma (STU:RPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPRX:Mexico

Address

110 East 59th Street, FL 33, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.